Small-animal positron emission tomography enables the assessment of the brain's two main energy substrates: glucose and ketones. In the present method, 11C-acetoacetate and 18F-fluorodeoxyglucose are injected sequentially in each animal, and their uptake is measured quantitatively in specific brain regions determined from the magnetic resonance images.
We present a method for comparing the uptake of the brain's two key energy substrates: glucose and ketones (acetoacetate [AcAc] in this case) in the rat. The developed method is a small-animal positron emission tomography (PET) protocol, in which 11C-AcAc and 18F-fluorodeoxyglucose (18F-FDG) are injected sequentially in each animal. This dual tracer PET acquisition is possible because of the short half-life of 11C (20.4 min). The rats also undergo a magnetic resonance imaging (MRI) acquisition seven days before the PET protocol. Prior to image analysis, PET and MRI images are coregistered to allow the measurement of regional cerebral uptake (cortex, hippocampus, striatum, and cerebellum). A quantitative measure of 11C-AcAc and 18F-FDG brain uptake (cerebral metabolic rate; μmol/100 g/min) is determined by kinetic modeling using the image-derived input function (IDIF) method. Our new dual tracer PET protocol is robust and flexible; the two tracers used can be replaced by different radiotracers to evaluate other processes in the brain. Moreover, our protocol is applicable to the study of brain fuel supply in multiple conditions such as normal aging and neurodegenerative pathologies such as Alzheimer's and Parkinson's diseases.
Context and Rationale
Positron emission tomography (PET) enables the minimally-invasive study of functional processes in the brain. Glucose is the brain's main energy substrate, but in conditions of glucose deficiency, ketones (acetoacetate [AcAc] and β-hydroxybutyrate) are the main alternative energy substrates. Brain energy metabolism has been widely studied by PET using the most common PET tracer, 18F-fluorodeoxyglucose (18F-FDG), a glucose analog. Our group recently developed a novel radiotracer –11C-AcAc – to measure brain ketone metabolism1. Magnetic resonance imaging (MRI) is a much higher resolution technique (0.1 mm × 0.1 mm in-plane resolution) than PET, and is needed to clearly localize anatomical brain regions required for the regional PET analysis of brain energy metabolism.
PET data are commonly expressed as standardized uptake values (SUV)2-6. SUV are the tissue activity concentration normalized by the fraction of the injected dose/unit weight, as initially proposed over 70 years ago7. These units are still widely used because they require simpler PET acquisition and image analysis methodologies. However, an important limitation is that SUV are relative not absolute units, making it difficult to compare results across different studies. This difficulty of comparison may contribute to contradictory findings in the literature on brain glucose uptake in the elderly8. Therefore, the quantitative cerebral metabolic rate (CMR; μmol/100 g/min) has particular advantages9-11. Generating CMR values requires a dynamic PET acquisition and the plasma radioactivity counts as a function of time, i.e. the plasma time-activity curve (TAC) or input function. The input function can be obtained by multiple blood samplings throughout the PET acquisition9,12 or by the image-derived input function (IDIF) method, in which a region of interest is drawn on a blood pool (heart's left ventricle or major artery)11,13-16.
Goal
The aim of our method was to quantitatively compare for the first time the uptake of the brain's two key energy substrates, glucose and ketones, using PET and MRI in rodents. 11C-AcAc and 18F-FDG were used sequentially in the same animal. The protocol was designed to measure regional uptakes in different relevant brain structures (cortex, hippocampus, striatum, and cerebellum) clearly visible in the MR images. The protocol was also specifically intended to permit quantitative analysis of tracer brain uptake, i.e. CMR of both 18F-FDG and 11C-AcAc. Although this protocol was developed to study brain energy substrates, the radiotracers we used could be replaced by others, and the same methodology can be used to study different brain functional processes.
Advantages over existing methods
PET and MRI do not require the animal to be sacrificed after the acquisition. Therefore, follow-up studies of treatments are possible. Thus, baseline data followed by an experimental condition can be measured within the same animal, thereby reducing both biological variability and the number of animals required. A key advantage of our dual tracer PET protocol is to compare both tracers uptake in the same animal under the same physiological conditions within the same imaging session, thereby reducing even more biological variability and systematic discrepancies. This dual tracer PET protocol is feasible primarily because of the short physical half-life of 11C (20.4 min) and the fast biological washout of 11C-AcAc, which leave minimal residual 11C radioactivity during the second acquisition with 18F-FDG. The MRI scan is an important feature of this protocol as it enables the tracer uptake to be studied in specific brain areas. In addition, this method enables an absolute quantitative measure of brain tracer uptake in contrast to relative units obtained by the SUV method. Finally, 11C-AcAc images have a low signal-to-noise ratio because of relatively low brain AcAc uptake under physiological conditions, which makes automatic 11C-AcAc and MR images registration challenging. Hence, because 11C-AcAc and 18F-FDG acquisitions are sequential (no motion of the animal), the 18F-FDG to MRI alignment can be applied to 11C-AcAc images.
Key papers where the protocol has been used
We have used the dual tracer PET protocol in a study involving the comparison of the fasted state and the ketogenic diet (KD) in young rats2. We showed that both fasting and the KD increase significantly both 11C-AcAc and 18F-FDG brain uptake. However, these were not quantitative results as we did not use the dynamic PET imaging and tracer kinetic modeling methodology at that time. Thereafter, we undertook a regional and quantitative study of brain metabolism in aged rats, where the effect of aging and a KD were evaluated on brain 11C-AcAc and 18F-FDG uptake11. We also showed that the percentage of distribution across brain regions was different between 11C-AcAc and 18F-FDG. Furthermore, not only the CMR of 11C-AcAc but also that of 18F-FDG was increased in the whole brain as well as in the striatum of aged rats on the KD.
All experiments were completed in accordance with the Animal Care and Use Committee at the Université de Sherbrooke and with the Canadian Council on Animal Care. The experimental protocol was approved by the Institutional Animal Research Ethics Review Board (protocol #011-09).
1. Brain Anatomy with MRI
2. Dual Tracer PET Acquisitions
3. Plasma Glucose and AcAc Analysis
4. Quantitative PET Analysis
As seen in Figure 2,11C-AcAc uptake is low within the brain itself. As mentioned earlier, ketones consumption by the brain is very low on a short-term fasting. 11C-AcAc uptake is higher in the tongue and cheek muscles. Indeed, ketones are rapidly taken up by rat skeletal muscles23. In contrast, 18F-FDG uptake is mostly in the brain and the cheek muscles. Figure 2 shows that during the coregistration process, MR images are fixed and PET images move due to an alignment in the axial plane.
We use the Patlak kinetic model20,21 to determine brain uptake, which has been previously used for 11C-ketone and 18F-FDG kinetic modeling9,12,24,25. This model uses equation 1, where the measured PET activity (CTissue) is divided by plasma activity (CP) and plotted at a normalized time. The variable Κ represents brain influx and V is the tracers distribution volume. After brain uptake steady state is achieved, the curve results in a straight line (Figure 4A). The slope represents brain influx (K). Typical values of brain influx (K) and distribution volume (V) in the whole brain for 18F-FDG are ~0.0165 min-1 and ~0.6425 ml blood/ml tissue, respectively (Figure 4B). As for 11C-AcAc, typical values are ~0.0325 min-1 and ~0.5315 ml blood/ml tissue.
Cerebral metabolic rate of glucose (CMRglc) and AcAc (CMRAcAc) are calculated according to equations 2 and 3. Brain influx and plasma concentrations are required. For CMRglc, the lumped constant (LC) is used to convert 18F-FDG uptake to glucose uptake. We use a LC value of 0.48, as previously reported in rats22. No constant is used for CMRAcAc calculation as the radiotracer has the exact same chemical formula as the endogenous molecule.
One can expect whole brain CMRglc and CMRAcAc of approximately 24 μmol/100 g/min and 3 μmol/100 g/min, respectively, in healthy adult rats fasted for 18 hr prior the PET acquisitions11. In the rat, CMRAcAc is therefore about 12% of that of CMRglc.
Figure 1. Plasma time-activity curve (TAC) assessment. A) Volume of interest drawn on the blood pool in the left ventricle of the heart using a manual drawing tool. This is a 18F-FDG image showing the average radioactivity for the first 60 sec after the injection. B) 18F-FDG plasma TAC obtained by image-derived input function (IDIF; black), the two plasma samples collected 30 min (red) and 37.5 min (orange) after the injection and 18F-FDG plasma TAC after correction with radioactivity counts of the two plasma samples (blue).
Click here to view larger image.
Figure 2. PET/MRI automatic coregistration process. Axial PET and MR images before (left) and after (right) automatic coregistration with PMOD software. 18F-FDG (top) and 11C-AcAc (bottom) images are shown. 11C-AcAc/MRI coregistration is performed using the 18F-FDG/MRI transformation parameters.
Click here to view larger image.
Figure 3. Volumes of interest (VOIs) drawing. VOIs drawn on axial MR images (top). VOIs applied to 18F-FDG coregistered images (bottom). WB: whole brain; Cx: cortex; Hp: hippocampus; St: striatum; Cb: cerebellum.
Click here to view larger image.
Figure 4. Kinetic modeling of brain 18F-FDG uptake using PMOD software. A) Patlak plot of 18F-FDG uptake in the whole brain. Y-axis correspond to the measured PET activity (CTissue) divided by plasma activity (CP) and x-axis correspond to the normalized time. The curve results in a straight line once steady state is reached. The slope represents brain influx (K). B) Cerebral metabolic rate of glucose (MRGlu.) and plot parameters of the corresponding 18F-FDG acquisition, where Plasma Gluc. is the plasma glucose concentration, Max. Err. is the maximal relative deviation from the Patlak regression line, Slope is the brain influx (K) and Intercept is the distribution volume (V).
Click here to view larger image.
Critical steps
A critical step in this dual tracer PET protocol is to be able to simultaneously scan the heart's left ventricle and the brain at the same time. This requires a PET scanner with a sufficient axial length, i.e. a minimum of 7.5 cm. A few test scans are needed to determine the exact position of the scanner table (x, y, and z values), where the brain and the heart are scanned correctly.
Tracer injection is also a crucial point for a successful PET acquisition. The catheter must be correctly inserted in the vein. Heparinized saline solution should flow into the vein smoothly without blood clotting. For a quantitative measure of brain uptake, an accurate plasma TAC is essential. When drawing the VOI on blood in the left ventricle, it is important to include the fewest possible tissue pixels. Blood samples are also crucial to correct the plasma TAC derived from the PET images. Indeed, as seen in Figure 1B, radioactivity in plasma samples may be different than in the IDIF. This is due to the spill-in effect in the last time frames (contamination of blood by radiation in adjacent tissues)26, which affects the IDIF. The brain MR image is essential for regional brain analysis. After the coregistration process, the alignment of PET and MR images of every brain slice should be verified to ensure that the subsequent PET regional brain analysis is accurate. Finally, a good fit of data to the Patlak plot is required for accurate calculation of CMR. Data should be as linear as possible; if not, the plasma and brain TAC should be rechecked.
Limitations
A significant limitation of PET imaging is that it provides no information on the chemical status of the radiotracer, i.e. degradation to other metabolites in the brain. Indeed,18F-FDG is taken up by brain cells, where it is trapped as 18F-FDG-6-phosphate. This contrasts with nuclear magnetic resonance spectroscopy (NMRS) where the labeled atom can be monitored in multiple metabolic pathways27-29. However, PET requires very low amounts of radiotracer (10-12-10-9 M) compared to NMRS, and therefore better reflects physiological conditions. Another limitation comes from the plasma TAC derived from the PET images, which can be inexact because of the spill-out effect from blood to tissues in the first time frames26. Indeed, the present method does not include blood sampling in the first time frames. When drawing the VOI in the left ventricle, heart tissue may be included in the VOI without noticing because of heart beat, which may affect the plasma TAC. Indeed, the present method does not include electrocardiogram-gated PET acquisitions. The multiple blood sampling method is the gold standard for the most accurate plasma TAC, but remains demanding and invasive for small animals. Indeed, this technique would require approximately 18 blood samplings per scan for both scan, which would represent a considerable volume of blood sampled. Finally, for 11C-AcAc acquisitions, no correction for loss of 11C-CO2 from the tissue is performed. However, previous 11C-ketone PET studies showed that loss of 11C-CO2 had minimal impact on data, since the Patlak plot was well described by a straight line, and did not correct data for this loss24,25.
Possible modifications
This protocol is also applicable for the study of mice models. Fasting can be shortened to 6 hr prior to the PET scan. However, with less than 6 hr, 11C-AcAc brain uptake will not be high enough for accurate CMR computation. Indeed, the brain consumes more ketones as the fasting period is prolonged. We have previously shown that after a 48 hr fasting, brain 11C-AcAc uptake increases by 160% and that brain 18F-FDG uptake also increases by 277%2. Electrocardiogram-gated PET acquisitions can be performed and may enable a more accurate plasma TAC. One can use another type of anesthetic such as propofol or ketamine depending of the Institutional Animal Care and Use guidelines. If an injection of anesthetic needs to be done during the dual PET tracer protocol, it should be performed between the two scans and attention should be paid not to move the animal. A longer delay is also possible between the two PET scans to reduce residual radioactivity from 11C in the 18F-FDG scan. However, the total period for anesthesia should be kept as short as possible since anesthesia decreases brain metabolism30. For quantitative PET analysis, any custom software enabling coregistration process and kinetic modeling can be used. If the automatic PET-MRI coregistration process is not possible, the registration can be performed manually. It is however a longer process and prone to human error. Finally, the two-tissue compartment kinetic model is also a good model for 18F-FDG brain uptake analysis and has been previously used in animal PET studies10,12. As for 11C-AcAc, the one and two-tissue compartment models were shown to give identical results as the Patlak model24,25.
Significance of the method
The presented method permits sequential measurement of regional brain uptake of two PET tracers and, hence, their comparison in the same animal under the same conditions. Therefore, this protocol is ideal for comparative studies of brain metabolic pathways using these PET tracers. Since the animals recover from the procedure, it can be repeated after an experimental intervention. This method also enables the absolute quantitative assessment of cerebral metabolic rates (μmol/100 g/min) in contrast to relative data obtained by the SUV method.
Future applications
The investigation of brain ketone and glucose metabolism using 11C-AcAc and 18F-FDG uptake by PET is relevant in many physiological and pathological processes such as aging, neurodegenerative patterns and tumor expansion or treatment. Other PET tracers can be studied with the present protocol: 11C-palmitate and 18F-fluorothioheptadecanoic acid uptake can be used to evaluate fatty acids esterification in conditions such as aging or type 2 diabetes.11C-Pittsburgh Compound-B, which binds fibrillar amyloid-β plaques, could potentially be used in conjunction with 18F-FDG for the study of Alzheimer-like brain pathologies. Furthermore, 18F-fluorodopamine is useful to evaluate dopamine circuits in disease such as Parkinson. This dual tracer PET and MRI protocol can be applied to the study of other organs such as the liver, heart, kidney, or tumors.
The authors have nothing to disclose.
This study was financially supported by the Fonds de la recherche en santé du Québec, Canadian Institutes of Health Research, Canadian Foundation for Innovation and the Canada Research Chairs Secretariat (SCC). The Sherbrooke Molecular Imaging Center is part of the FRQS-funded Étienne-Le Bel Clinical Research Center. The authors thank Mélanie Fortier, Jennifer Tremblay-Mercier, Alexandre Courchesne-Loyer, Dr. Fabien Pifferi, Dr. M'hamed Bentourkia, Dr. Otman Sarrhini, Dr. Jacques Rousseau, Caroline Mathieu, and Mélanie Archambault for generous support and technical assistance. The authors would like to thank the image analysis and visualization platform (http://pavi.dinf.usherbrooke.ca) for their help.
MRI scanner | Varian | 7 Tesla | |
Small-animal PET scanner | Gamma Medica | Lab-PET/-Triumph | |
Heat mat | Sunbeam | PN 143937 | |
Heater system | SA Instruments | 761 100 Rev B | |
Respiratory gating | SA Instruments | SAII's P-resp | |
Clinical chemistry analyzer | Siemens Healthcare Diagnosis | 765000.931 | Dimension Xpand Plus |
Polyethylene tubing 50 | Becton Dickinson | 427411 | |
Injection pump | KD Scientific | Model 210 | |
Gamma-counter | GMI | Packard Cobra II | |
Centrifuge | Thermo Scientific | 75002416 | Heraeus Pico 21 |
PMOD software | PMOD Technologies | PMOD 3.2 version | |
Geiger counter | Fluke Biomedical | ASM-990 | Advanced Survey Meter |
Reagent | |||
Name of the Reagent | Company | Catalogue Number | Comments (optional) |
Isoflurane | Abbott Laboratories, Ltd | B506 | |
0.9% NaCl solution | Hospira | 4888010 | |
Heparin | Sandoz | 1004336 | |
Isopropenyl acetate | Aldrich | 11778 | 99% |
Methyllithium | Aldrich | 197343 | 1.6 M |
THF | Aldrich | 87371 | |
Flex reagent cartridge glucose | Siemens Healthcare Diagnosis | DF40 | |
Trizma base | Sigma | T6066-500G | prepare tris buffer 100 mM pH 7.0 |
Sodium oxamate | Sigma | O2751 | 20 mM |
NADH | Roche | 10128015001 | 0.15 mM |
b-Hydroxybutyrate dehydrogenase | Toyobo | HBD-301 | 1 U/ml |